In particular, a phase IIa, open-label trial conducted on 17 Asian patients with previously treated CCA harboring FGFR alterations (10 FGFR2 fusions, four FGFR2 mutations, one FGFR3 fusion, and two FGFR3 mutations) observed a partial response (PR) and stable disease (SD) in 46.7% and 33.3% of cases, respectively [73,74]. This evidence concerns the gene FGFR2 and cholangiocarcinoma.